Ivan Leontovyc

Ivan Leontovyc

Auto-generated profile, based on publicly available information

Ivan Leontovyc

Institute for Clinical and Experimental Medicine

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2017 in The Review of Diabetic Studies
Verified
Journal Article
Open access
BVBarbora Voglová
Barbora Voglová
MZMartina Zahradnická
Martina Zahradnická
PGPeter Girman
Peter Girman
JKJan Kriz
Jan Kriz
ZBZuzana Berkova
Zuzana Berkova
FSFrantisek Saudek
Frantisek Saudek
Pancreas transplantation (PTx) represents the method of choice in type 1 diabetic patients with conservatively intractable hypoglycemia unawareness syndrome. In 2005, the Institute for Clinical and Experimental Medicine (IKEM) launched a program to investigate the safety potential of islet transplantation (ITx) in comparison to PTx. This study aims to compare the results of PTx and ITx regarding severe hypoglycemia elimination, metabolic control, and complication rate. We analyzed the results of 30 patients undergoing ITx and 49 patients treated with PTx. All patients were C-peptide-negative and suffered from hypoglycemia unawareness syndrome. Patients in the ITx group received a mean number of 12,349 (6,387-15,331) IEQ/kg/person administered percutaneously into the portal vein under local anesthesia and radiological control. The islet number was reached by 1-3 applications, as needed. In both groups, we evaluated glycated hemoglobin, insulin dose, fasting and stimulated C-peptide, frequency of severe hypoglycemia, and complications. We used the Mann Whitney test, Wilcoxon signed-rank test, and paired t-test for analysis. We also individually assessed the ITx outcomes for each patient according to recently suggested criteria established at the EPITA meeting in Igls. Most of the recipients showed a significant improvement in metabolic control one and two years after ITx, with a significant decrease in HbA1c, significant elevation of fasting and stimulated C-peptide, and a markedly significant reduction in insulin dose and the frequency of severe hypoglycemia. Seventeen percent of ITx recipients were temporarily insulin-independent. The results in the PTx group were comparable to those in the ITx group, with 73% graft survival and insulin independence in year 1, 68% 2 years and 55% 5 years after transplantation. There was a higher rate of complications related to the procedure in the PTx group. Severe hypoglycemia was eliminated in the majority of both ITx and PTx recipients. This report proves the successful initiation of pancreatic islet transplantation in a center with a well-established PTx program. ITx has been shown to be the method of choice for hypoglycemia unawareness syndrome, and may be considered for application in clinical practice if conservative options are exhausted.

25 February 2022 in Transplantation Proceedings
Verified
Journal Article
Closed access
FSFrantisek Saudek
Frantisek Saudek
ZHZuzana Hladiková
Zuzana Hladiková
BHBarbora Hagerf
Barbora Hagerf
LNLenka Nemetova
Lenka Nemetova
PGPeter Girman
Peter Girman
JFJiri Fronek
Jiri Fronek

14 August 2017 in PLOS ONE
Verified
Journal Article
Open access
PDF file
ILIvan Leontovyc
Ivan Leontovyc
DHDavid Habart
David Habart
SLSarka Loukotova
Sarka Loukotova
LKLucie Kosinova
Lucie Kosinova
JKJan Kriz
Jan Kriz
TKTomas Koblas
Tomas Koblas
Cell reprogramming requires efficient delivery of reprogramming transcription factors into the cell nucleus. Here, we compared the robustness and workload of two protein delivery methods that avoid the risk of genomic integration. The first method is based on fusion of the protein of interest to a protein transduction domain (PTD) for delivery across the membranes of target cells. The second method relies on de novo synthesis of the protein of interest inside the target cells utilizing synthetic mRNA (syn-mRNA) as a template. We established a Cre/lox reporter system in three different cell types derived from human (PANC-1, HEK293) and rat (BRIN-BD11) tissues and used Cre recombinase to model a protein of interest. The system allowed constitutive expression of red fluorescence protein (RFP), while green fluorescence protein (GFP) was expressed only after the genomic action of Cre recombinase. The efficiency of protein delivery into cell nuclei was quantified as the frequency of GFP+ cells in the total cell number. The PTD method showed good efficiency only in BRIN-BD11 cells (68%), whereas it failed in PANC-1 and HEK293 cells. By contrast, the syn-mRNA method was highly effective in all three cell types (29–71%). We conclude that using synthetic mRNA is a more robust and less labor-intensive approach than using the PTD-fusion alternative.

1 January 2021 in Folia Biologica
Verified
Journal Article
Open access
PDF file
ILIvan Leontovyč
Ivan Leontovyč
TKT. Koblas
T. Koblas
ZBZ. Berková
Z. Berková
KBK. Bittenglova
K. Bittenglova
ALA. Leontovyc
A. Leontovyc
FSF. Saudek
F. Saudek
Clostridial collagenases are essential biotechnological tissue dissociation agents owing to their ability to cleave different types of collagen. Standardization of collagenase-based protocols has been hampered by impurities in products manufactured from Clostridium histolyticum . To enhance the purification process, we produced recombinant collagenase classes G and H, taking advantage of the Escherichia coli expression system. The respective gene sequences were derived from C. histolyticum and modified by addition of a C-terminal polyhistidine tag. Harvested bacteria were lysed and the collagenase protein was affinity purified using a His-tag column. The purity, identity, integrity of the eluted collagenases G and H were determined by SDS electrophoresis and Western blot. The proteolytic activity of the collagenase G and H blend (rColGH) was determined by the standard FALGPA assay. The tissue dissociation activity was verified using a standardized method for isolation of rat pancreatic islets. Biocompatibility of the blend was validated by a standardized viability assay on the isolated islets. Two batches of rColGH were produced and compared to a commercially available collagenase. Based on our results, we conclude that rColGH is a functional and non-toxic novel recombinant collagenase worth further characterization and blend optimization in order to make it a competitive commercial product.

14 September 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
KBKaterina Bittenglova
Katerina Bittenglova
KZKlara Zacharovova
Klara Zacharovova
FTFilip Tichanek
Filip Tichanek
ILIvan Leontovyc
Ivan Leontovyc
PGPeter Girman
Peter Girman
TKTomas Koblas
Tomas Koblas
Adult pancreatic β-cells are mostly locked in quiescence, limiting large-scale analysis of their cell cycle. To overcome this limitation, we used synthetic in vitro transcribed mRNAs encoding Cyclin D1 and CDK4 to induce proliferation in up to 70% of primary rat β-cells. Flow cytometry-based analysis of cell-cycle markers revealed substantial heterogeneity in β-cell cell-cycle progression, identifying five distinct groups of proliferating β-cells based on G1 entry timing. Total cell-cycle length ranged from approximately 26 to 34 hours and was primarily determined by variability in G1 duration (13-19 hours). In the fastest-dividing β-cells, G1, S, and G2M lasted approximately 13, 6, and 7 hours, respectively, whereas later-entering β-cells exhibited progressively longer G1 phase. Additionally, we identified a small β-cell subpopulation that failed to complete division and may have exited the cell cycle. These findings reveal cell-cycle entry and G1 progression as a major source of heterogeneity in β-cell proliferation and provide quantitative benchmark for developing strategies to enhance controlled β-cell regeneration in diabetes.